Stockreport

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Werewolf Therapeutics, Inc.  (HOWL) 
PDF Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “ [Read more]